Brii Biosciences (HKSE:02137) Capex-to-Revenue : 0.00 (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Brii Biosciences Capex-to-Revenue?

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue.

Brii Biosciences's Capital Expenditure for the six months ended in Dec. 2023 was HK$0.00 Mil. Its Revenue for the six months ended in Dec. 2023 was HK$0.00 Mil.

GuruFocus do not calculate Capex-to-Revenue if the revenue is negative.

Brii Biosciences Capex-to-Revenue Historical Data

The historical data trend for Brii Biosciences's Capex-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Brii Biosciences Capex-to-Revenue Chart

Brii Biosciences Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Capex-to-Revenue

2.70

80.39

Brii Biosciences Semi-Annual Data
	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Capex-to-Revenue	Get a 7-Day Free Trial				-	-	-	-	-

Competitive Comparison of Brii Biosciences's Capex-to-Revenue

For the Biotechnology subindustry, Brii Biosciences's Capex-to-Revenue, along with its competitors' market caps and Capex-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Brii Biosciences's Capex-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Brii Biosciences's Capex-to-Revenue distribution charts can be found below:

* The bar in red indicates where Brii Biosciences's Capex-to-Revenue falls into.

Brii Biosciences Capex-to-Revenue Calculation

Brii Biosciences's Capex-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Capex-to-Revenue	=	- Capital Expenditure	/	Revenue
	=	- (-54.26)	/	0.675
	=	80.39

Brii Biosciences's Capex-to-Revenue for the quarter that ended in Dec. 2023 is calculated as

Capex-to-Revenue	=	- Capital Expenditure	/	Revenue
	=	- (0)	/	0
	=	N/A

Brii Biosciences (HKSE:02137) Capex-to-Revenue Explanation

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue. The ratio shows how aggressively the company reinvests its revenue back into productive assets. However, a high ratio potentially indicates that the company has invested too much in innovation and infrastructure, taking up funds that could be used to boost productivity and increase revenue. Therefore, a high Capex to Revenue Ratio could be a positive or a negative sign depending on how effectively a company converts those investments into future earnings.

Brii Biosciences Capex-to-Revenue Related Terms

Thank you for viewing the detailed overview of Brii Biosciences's Capex-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Brii Biosciences (HKSE:02137) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Brii Biosciences Ltd (HKSE:02137) » Definitions » Capex-to-Revenue

Comparable Companies

Traded in Other Exchanges

BRIBF:USA 7SS:Germany

Address

No. 1 North Yongtaizhuang Road, 3rd Floor, Building 7, Zhongguancun Dongsheng, International Science Park, Haidian District, Beijing, CHN, 100192

Website

https://www.briibio.com

Brii Biosciences Ltd is a biotechnology company based in China and the United States. It is committed towards developing advancing therapies for infectious diseases, such as HBV, HIV, MDR/XDR gram-negative infections, and other illnesses, such as the CNS diseases, which have public health burdens in China and worldwide. The company's pipeline of products includes more than 10 product candidates that focus on infectious diseases and mental illnesses.

Executives

Hong Zhi	2101 Beneficial owner
Xyxy Holdings Ltd.	2201 Interest of corporation controlled by you
Booming Passion Limited	2101 Beneficial owner
Boyu Capital Fund Iii, L.p.	2201 Interest of corporation controlled by you
Boyu Capital General Partner Iii, L.p.	2201 Interest of corporation controlled by you
Boyu Capital General Partner Iii, Ltd	2201 Interest of corporation controlled by you
Tong Xiaomeng	2201 Interest of corporation controlled by you
Boyu Group, Llc	2201 Interest of corporation controlled by you
Boyu Capital Group Holdings Ltd	2201 Interest of corporation controlled by you
Jpmorgan Chase & Co.	2201 Interest of corporation controlled by you
Invesco Advisers, Inc.	2102 Investment manager
Ma Yun	2201 Interest of corporation controlled by you
Yunfeng Investment Iii, Ltd.	2201 Interest of corporation controlled by you
Yunfeng Fund Iii, L.p.	2201 Interest of corporation controlled by you
Yf Bright Insight Limited	2101 Beneficial owner

Brii Biosciences (HKSE:02137) Headlines

No Headlines